CY1105010T1 - Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου - Google Patents

Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου

Info

Publication number
CY1105010T1
CY1105010T1 CY20051100274T CY051100274T CY1105010T1 CY 1105010 T1 CY1105010 T1 CY 1105010T1 CY 20051100274 T CY20051100274 T CY 20051100274T CY 051100274 T CY051100274 T CY 051100274T CY 1105010 T1 CY1105010 T1 CY 1105010T1
Authority
CY
Cyprus
Prior art keywords
protein
rsv
syndicate
respiratory
virus
Prior art date
Application number
CY20051100274T
Other languages
English (en)
Inventor
Gerald E. Hancock
Paul W. Tebbey
Original Assignee
Wyeth Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Corporation filed Critical Wyeth Holdings Corporation
Publication of CY1105010T1 publication Critical patent/CY1105010T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Αποκαλύπτεται μία μεταβληθείσα G πρωτεΐνη ή τμήμα αυτής του RSV που διατηρεί ανοσογονικότητα και η οποία όταν ενσωματώνεται σε μία ανοσογονική σύνθεση ή εμβόλιο και χορηγείται σε ένα σπονδυλωτό δεν διεγείρει αυξημένη ασθένεια (π.χ., άτυπη πνευμονική φλεγμονή, όπως πνευμονική ηωζινοφιλία) κατά τη μετέπειτα μόλυνση με RSV. Σε μία συγκεκριμένη πραγματοποίηση, η μεταβληθείσα G πρωτεΐνη περιλαμβάνει μία μεταβολή στη περιοχή από το αμινοξύ 184 έως το αμινοξύ 198. Αποκαλύπτονται επίσης ανοσογονικές συνθέσεις και εμβόλια που περιλαμβάνουν τη μεταβληθείσα RSV G πρωτεΐνη και που προαιρετικά περιλαμβάνουν RSV F πρωτεΐνη.
CY20051100274T 1997-09-19 2005-02-24 Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου CY1105010T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5968497P 1997-09-19 1997-09-19
US8486398P 1998-05-08 1998-05-08
PCT/US1998/019656 WO1999014334A1 (en) 1997-09-19 1998-09-17 Peptides derived from the attachment (g) protein of respiratory syncytial virus

Publications (1)

Publication Number Publication Date
CY1105010T1 true CY1105010T1 (el) 2010-03-03

Family

ID=26739056

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20051100274T CY1105010T1 (el) 1997-09-19 2005-02-24 Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου

Country Status (13)

Country Link
EP (1) EP1015595B1 (el)
JP (1) JP2001516583A (el)
KR (1) KR100550132B1 (el)
CN (1) CN1259422C (el)
AT (1) ATE287957T1 (el)
AU (1) AU751022B2 (el)
BR (1) BR9812240A (el)
CA (1) CA2302833C (el)
CY (1) CY1105010T1 (el)
DE (1) DE69828801T2 (el)
ES (1) ES2236946T3 (el)
PT (1) PT1015595E (el)
WO (1) WO1999014334A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1334119T4 (en) * 2000-10-18 2019-03-18 The Government Of The Us Secretary Department Of Health And Human Services Compositions and Methods for Modulating RSV Infection and Immunity
AUPR520201A0 (en) * 2001-05-23 2001-06-14 Commonwealth Scientific And Industrial Research Organisation Antiviral compounds
NL1019228C1 (nl) 2001-10-25 2003-04-28 Duynstee Holding B V Verbeterd gecombineerd ophang- en verlichtingssysteem voor bijvoorbeeld schilderijen e.d.
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
DE10219219A1 (de) 2002-04-29 2003-11-06 Tampoflex Gmbh Druckanlage
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
AU2005260580A1 (en) * 2004-06-30 2006-01-12 Wyeth Holdings Corporation Recombinant rsv strains with altered g protein
EP2181121A4 (en) * 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
EP3508505A1 (en) 2007-12-24 2019-07-10 ID Biomedical Corporation of Quebec Recombinant rsv antigens
US8889146B2 (en) 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
PE20121541A1 (es) 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa Antigenos de virus de sincicio respiratorio recombinantes
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
CN102481309B (zh) * 2009-07-17 2014-06-18 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726577B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
AU722494C (en) * 1996-06-05 2007-03-29 Commonwealth Scientific And Industrial Research Organisation Viral peptides with structural homology to protein G of respiratory syncytial virus
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide

Also Published As

Publication number Publication date
DE69828801D1 (de) 2005-03-03
PT1015595E (pt) 2005-05-31
AU751022B2 (en) 2002-08-08
ATE287957T1 (de) 2005-02-15
ES2236946T3 (es) 2005-07-16
CN1322250A (zh) 2001-11-14
DE69828801T2 (de) 2005-07-14
AU9572598A (en) 1999-04-05
WO1999014334A1 (en) 1999-03-25
JP2001516583A (ja) 2001-10-02
KR100550132B1 (ko) 2006-02-08
EP1015595B1 (en) 2005-01-26
BR9812240A (pt) 2000-07-18
KR20010030620A (ko) 2001-04-16
CN1259422C (zh) 2006-06-14
EP1015595A1 (en) 2000-07-05
CA2302833A1 (en) 1999-03-25
CA2302833C (en) 2007-05-08

Similar Documents

Publication Publication Date Title
CY1105010T1 (el) Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
BR9306820A (pt) Conjugado de um antígeno fracamente imunogênico e um veículo peptideo sintetico vacina processos para melhorar a imunogenicidade de uma molecula de antigeno fracamente imunogenico e para imunizar um hospedeiro mamífero
MA24638A1 (fr) Vaccin
BR9609795A (pt) Derivados de ciclosporina tendo um efeito anti-hiv
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
BR9201015A (pt) Conjugado de proteina,composto,processo para preparar o conjugado,composicoes farmaceuticas e uso
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
BR9704879A (pt) Composição de vacina e uso de um vírus cav vivo
HUP0202537A2 (hu) Vakcinakészítmény és eljárás annak alkalmazására
DK0491628T3 (da) Lipopeptider inducerende cytotoksiske T-lymfocytter og deres anvendelse som vacciner
HUP9904171A2 (hu) A ragadós száj- és körömfájás vírusok immunogén peptidjei
CY1107620T1 (el) Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis
DE69415462D1 (de) Synthetischen peptiden und impfstoffe gegen parvovirus
ATE221786T1 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
ATE356140T1 (de) Gd3 mimetische peptide
ATE353669T1 (de) Allergievakzine sowie ihre herstellung
ATE154244T1 (de) Induzierung eines schutzes gegen virale infektionen
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
DE69433760D1 (de) Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält
RU93058622A (ru) Композиции на основе фактора лелистада, вакцины, диагностические наборы, способ диагностики
DE60022995D1 (de) Impfstoff
ATE177010T1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
DE216901T1 (de) Immunogenes antigen-traeger-proteinkonjugat zur verwendung in impfstoffen gegen malaria.